Orexigen Finds Partner for Obesity Drug Prior to Regulatory Approval Decision
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 8 (Table of Contents)
Published: 13 Oct-2010
DOI: 10.3833/pdr.v2010.i8.1385 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Orexigen Therapeutics has secured Takeda Pharmaceutical as a partner for its obesity drug Contrave® (naltrexone SR/bupropion SR), which is awaiting marketing approval in the US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS